H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating on September 16.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Hold rating due to a combination of factors surrounding aTyr Pharma’s recent clinical trial results and future prospects. The Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis showed some promising outcomes, particularly in quality of life improvements, such as the King’s Sarcoidosis Questionnaire scores and Fatigue Assessment Scale scores. However, the study did not achieve its primary endpoint related to the reduction in mean daily oral corticosteroid dose, which raises concerns about the drug’s efficacy in meeting its primary objectives.
Despite the missed primary endpoint, the additional data presented at the European Respiratory Society Congress 2025 highlighted sustained clinical benefits across several health outcomes. These findings suggest that efzofitimod has the potential to improve patient quality of life and reduce steroid dependency. Nonetheless, the lack of primary endpoint achievement and the need for further regulatory discussions contribute to the cautious Hold rating, as the company seeks to establish a clear regulatory path forward for efzofitimod.
In another report released on September 16, Leerink Partners also downgraded the stock to a Hold with a $1.00 price target.